The Conversation (0)
Voyager Therapeutics announced positive results from their ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson’s disease.
Voyager Therapeutics (NASDAQ:VYGR) announced positive results from their ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson’s disease.
As quoted in the press release:
The results demonstrated durable, dose-dependent and time-dependent improvements across multiple measures of patients’ motor function after a one-time administration of the gene therapy. These measures include patient-reported diaries, Parkinson’s disease rating scales, and activities of daily living.
“We are very pleased with the updated results from our dose-escalation trial. By six months in Cohort 3, patients achieved the clinically meaningful improvements in motor symptoms that were observed in Cohort 2 and with even lower doses of their oral Parkinson’s medications, including levodopa,” said Bernard Ravina, M.D., M.S., chief medical officer of Voyager Therapeutics.
Click here to read the full press release.
Source: globenewswire.com